From: Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial
 | ITT | ITT-VP | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | Carrageenan | Placebo |  | Carrageenan | Placebo |  | ||||
 | n | % | n | % | p value | n | % | n | % | p value |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Male | 51 | 50.0% | 42 | 41.6% | Â | 29 | 49.2% | 24 | 40.7% | Â |
Female | 51 | 50.0% | 59 | 58.4% | 0.23* | 30 | 50.8% | 35 | 59.3% | 0.36* |
 | Mean | SD | Mean | SD |  | Mean | SD | Mean | SD |  |
Age, years | 33.7 | 12.9 | 33.3 | 12.9 | 0.84** | 31.6 | 12.0 | 32.6 | 12.9 | 0.65** |
Weight, kg | 74.0 | 15.4 | 73.8 | 15.7 | 0.95** | 71.5 | 13.1 | 70.1 | 13.8 | 0.56** |
Height, cm | 174.0 | 10.4 | 173.2 | 9.4 | 0.55** | 174.3 | 10.1 | 172.8 | 9.9 | 0.86** |
 | n | % | n | % |  | n | % | n | % |  |
Smoking status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Active smoker | 36 | 35.3% | 32 | 31.7% | 0.59* | 24 | 40.7% | 17 | 28.8% | 0.18* |
Passive smoker | 25 | 24.5% | 22 | 21.8% | 0.65* | 17 | 28.8% | 13 | 22.0% | 0.40* |
Active OR passive smoker | 44 | 43.1% | 40 | 39.6% | 0.61* | 30 | 50.8% | 21 | 35.6% | 0.09* |
 | Mean | SD | Mean | SD |  | Mean | SD | Mean | SD |  |
Baseline TSS | 6.3 | 2.0 | 6.4 | 1.9 | 0.56** | 6.3 | 2.0 | 6.4 | 1.7 | 0.77** |